Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield RB
Journal of the American Chemical Society (1963)
The 1963 JACS paper that introduced solid-phase peptide synthesis — anchoring the C-terminal amino acid to an insoluble polymer support and extending the chain through repeated coupling cycles. The methodology earned Merrifield the 1984 Nobel Prize in Chemistry and remains the workhorse of synthetic-peptide manufacturing six decades later.
This is the founding paper of solid-phase peptide synthesis (SPPS) — the technology that now produces essentially every chemically-synthesized therapeutic peptide on the modern market, from the SPPS-scale manufacturing of semaglutide and tirzepatide at multi-thousand-liter reactor scale through every research-grade peptide chemistry program in academic and biotech laboratories worldwide. Bruce Merrifield, working at the Rockefeller Institute, introduced the central idea: rather than build a peptide chain in solution (where each intermediate must be isolated, purified, and characterized before the next coupling step), build the chain while one end is covalently anchored to an insoluble polymeric support. Excess reagents and byproducts are then removed by simple washing of the resin rather than by chromatographic purification of each intermediate, the chain grows through repeated identical cycles of deprotection and coupling, and the full sequence can be assembled in a fraction of the time and labor that solution-phase synthesis requires.
The paper describes the synthesis of the model tetrapeptide Leu-Ala-Gly-Val. The C-terminal valine was attached to a chloromethylated polystyrene resin through its α-carboxyl group, with the α-amino group carrying a temporary tert-butoxycarbonyl (tBoc) protecting group. Each cycle proceeded as: (1) deprotect the α-amino group of the resin-bound amino acid with HCl in dioxane to liberate the free amine, (2) couple the next protected amino acid via its activated carboxyl group using dicyclohexylcarbodiimide (DCC), (3) wash the resin to remove excess reagents and byproducts, (4) repeat. After four cycles assembled the tetrapeptide on resin, the chain was cleaved from the support by saponification with aqueous sodium hydroxide. The product was identified by paper chromatography, amino acid analysis, and elemental analysis; the synthesis demonstrated the central methodology in proof-of-principle form.
Merrifield's methodology was the subject of his 1984 Nobel Prize in Chemistry, awarded "for his development of methodology for chemical synthesis on a solid matrix." The contemporary state of the art has moved substantially from the 1963 paper's tBoc-DCC chemistry — modern SPPS predominantly uses Fmoc (9-fluorenylmethoxycarbonyl) protection rather than tBoc, employs more efficient coupling reagents (HBTU, HATU, PyBOP, DIC/HOBt) than DCC, uses more sophisticated resin chemistries (Wang, Rink amide, 2-chlorotrityl chloride) than chloromethylated polystyrene, and cleaves with TFA rather than HF or NaOH — but the central idea of building the chain on a resin support through repeated identical cycles is unchanged from the 1963 paper. Every modern synthetic-peptide pharmaceutical descends methodologically from this paper.
The paper is a methodological proof-of-principle on a four-residue model peptide, not a clinical or biological study; per-cycle coupling efficiencies and the deletion/truncation/racemization failure modes that dominate contemporary process-scale SPPS were established in subsequent literature. The original chemistry (tBoc protection, HCl deprotection, HF or NaOH cleavage) was substantially refined over the following two decades; the modern Fmoc strategy was developed in the late 1970s and dominates current pharmaceutical manufacturing on safety and orthogonality grounds. The Isidro-Llobet, Álvarez, and Albericio, Chem Rev 2009, 109:2455–2504 canonical review of protecting-group strategies and the Behrendt, White, and Offer, J Pept Sci 2016, 22:4–27 advances-in-Fmoc-SPPS review are the contemporary methodology references that supersede the 1963 paper for current practice. The methodology is replicated and extended in tens of thousands of subsequent publications; the original Merrifield paper is cited as the foundational reference rather than for any specific contemporary technical detail. The peptide manufacturing technical reference dossier walks the modern SPPS landscape including the GLP-1-class scale-up that has dominated peptide-pharmaceutical capacity since 2020. The complementary recombinant-peptide pathway, founded by Goeddel et al. 1979 PNAS for insulin, addresses the manufacturing space for larger peptides and proteins that SPPS cannot economically reach.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.